Finci, Lorenzo I.
Chakrabarti, Mayukh http://orcid.org/0000-0003-2653-9728
Gulten, Gulcin
Finney, Joseph
Grose, Carissa
Fox, Tara
Yang, Renbin
Nissley, Dwight V. http://orcid.org/0000-0001-7523-116X
McCormick, Frank http://orcid.org/0000-0002-6619-7120
Esposito, Dominic http://orcid.org/0000-0002-9987-1687
Balius, Trent E. http://orcid.org/0000-0002-6811-4667
Simanshu, Dhirendra K. http://orcid.org/0000-0002-9717-4618
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (75N91019D00024)
Article History
Received: 22 September 2023
Accepted: 22 February 2024
First Online: 2 March 2024
Competing interests
: All authors, except F.M., have no competing interests. F.M. is a consultant for Ideaya Biosciences, Kura Oncology, Leidos Biomedical Research, Pfizer, Daiichi Sankyo, Amgen, PMV Pharma, OPNA-IO, and Quanta Therapeutics, has received research grants from Boehringer-Ingelheim, and is a consultant for and cofounder of BridgeBio Pharma.